Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$159.62 USD

159.62
10,622,418

-7.67 (-4.58%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $160.06 +0.44 (0.28%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (198 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

by Zacks Equity Research

AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.

PCE/Core PCE Numbers Came In Line With Expectations

by Zacks Equity Research

PCE/Core PCE Numbers Came In Line With Expectations

Mark Vickery headshot

PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses

by Mark Vickery

Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.

AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NOBL

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.

Sweta Killa headshot

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

by Sweta Killa

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Kinjel Shah headshot

4 Large Drug Stocks to Hold on to Amid Industry Challenges

by Kinjel Shah

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Ahan Chakraborty headshot

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

by Ahan Chakraborty

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for COWZ

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for COWZ

Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

by Kinjel Shah

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson (JNJ) Q1 Earnings Top Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

by Zacks Equity Research

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.